2017
Pharmacogenomics of off‐target adverse drug reactions
Garon SL, Pavlos RK, White KD, Brown NJ, Stone CA, Phillips EJ. Pharmacogenomics of off‐target adverse drug reactions. British Journal Of Clinical Pharmacology 2017, 83: 1896-1911. PMID: 28345177, PMCID: PMC5555876, DOI: 10.1111/bcp.13294.Peer-Reviewed Original ResearchConceptsAdverse drug reactionsSevere cutaneous adverse reactionsTarget adverse drug reactionsDrug reactionsImmunological memoryTherapeutic effectHuman leukocyte antigen (HLA) associationsCutaneous adverse reactionsStrong human leukocyte antigen (HLA) associationDrug therapeutic effectsIM-ADRsMaculopapular exanthemaClinical featuresOptimal therapySignificant morbidityAdverse reactionsAntigen associationsPharmacological actionsTherapeutic targetDisease pathophysiologyClinical phenotypePreclinical testingGreater riskDrug metabolismPatient safety
1996
Angiotensin converting enzyme inhibitor‐associated angioedema: higher risk in blacks than whites
Burkhart G, Brown N, Griffin M, Ray W, Hammerstrom T, Weiss S. Angiotensin converting enzyme inhibitor‐associated angioedema: higher risk in blacks than whites. Pharmacoepidemiology And Drug Safety 1996, 5: 149-154. PMID: 15073831, DOI: 10.1002/(sici)1099-1557(199605)5:3<149::aid-pds222>3.0.co;2-i.Peer-Reviewed Original ResearchCalcium channel blockersIncidence of angioedemaWhite patientsHigh riskGreater incidenceGreater riskEnzyme (ACE) inhibitor-associated angioedemaRate of angioedemaRetrospective cohort studyRisk of angioedemaACEI exposureACEI useACEI usersAngioedema incidenceCCB usersCohort studyAngioedema casesFirst episodeACEIsChannel blockersAngioedemaMedicaid recipientsFull cohortEnzyme inhibitorsChronic exposure